Anavex Life Sciences Corp (AVXL)
followers
·
Follow
1 like
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| CEO: | Christopher U. Missling |
| Employees: | 40 |
| Web site: | anavex.com |
|
630 5TH AVENUE, 20TH FLOOR, NEW YORK, NY, 10111
844-689-3939
| |
-
Formally known as:
- Anvx Lf Scn Corp
| Date | Ratio |
|---|---|
| 2006-06-13 | 6:1 |
| 2015-10-07 | 1:4 |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Anavex Life Sciences Corp. engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the. treatment of Alzheimer's disease. The company's drug candidate also comprises ANaVEX 3-71 which is. in Phase I clinical. trial for frontotemporal dementia and other dementia indications.
Please log in first to see chart